Behind the Novartis mega-merger
'Believe me, what is a short walk between our two headquarters is a big step for the new company,' said Alex Krauer, future chairman of Novartis, to a gathering of analysts in London on March 8. 'To combine two strong and successful companies as a merger of equals into an even stronger and more successful new entity represents a fascinating vision indeed.'
That 'fascinating vision' had already been given a round of applause by the financial community the previous day, when it was announced
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495